# Company Fact Sheet – June 2021

**Headquarters:** Nuvaira, Inc.

 6500 Wedgwood Ave

 Minneapolis, MN 55311

 763.450.2800

 www.nuvaira.com

**Number of Employees: approximately** 50

**Products and Intended use:** The Nuvaira® Lung Denervation System is a novel, catheter-based system designed to treat airway nerve hyperactivity, a common pathophysiologic underpinning of chronic obstructive pulmonary disease (COPD) and asthma. The Nuvaira system is comprised of a capital good (energy delivery console), specialized per-patient-use dNerva® Dual Cooled RF Catheters in multiple sizes to accommodate variable airway anatomy, and an Accessory Kit.

**Procedure:** TLD therapy is performed as an outpatient procedure under general anesthesia. The TLD catheter is introduced into the lung via a standard therapeutic bronchoscope. Energy is delivered to ablate the vagal pulmonary nerves while continuously cooling and protecting the patient’s airways. Both lungs are treated in one procedure, which takes about an hour. TLD leaves no foreign body implants in the lung, and most patients return home the day of the procedure.

**Clinical Trials:** To date over 250 patients have been treated with TLD across 5 clinical trials. Six peer reviewed publications document a positive long-term safety profile and sustained positive clinical impact of TLD in patients with COPD. AIRFLOW-3 is an investigational, randomized, sham-controlled, double-blinded, superiority designed pivotal trial that will complete enrollment of 400 patients in early 2022.

**Therapeutic Value Proposition:** The goal of TLD treatment is to improve clinical stability and reduce exacerbations in moderate-to-severe COPD patients with high symptom burden despite optimal medical management.

**Regulatory Approvals:** CE mark (2016)

Investigational Device Exemption (IDE) approval for the AIRFLOW-3 Clinical Trial (2018)

**Financing:** $159 million raised

**Intellectual Property:** + 75 patents issued and pending worldwide

**Media Inquiries:** Amy Wolter

 +1 (763) 450-5676

 info@nuvaira.com

# # #

In the US, the Nuvaira Lung Denervation System is limited by federal law to investigational use only.

Nuvaira and dNerva are registered trademarks of Nuvaira, Inc.